Screening commercially insured individuals for colorectal cancer is a high-value service, costing less per year of life saved than breast or cervical cancer screening.
This large-scale, national study shows geographic variation in provider supply and hospital access for low- and high-income communities following the Affordable Care Act.
This article presents a synthesis of opioid use disorder guidelines and a framework to link them to claims data and recognize higher-quality practice, monitor outcomes, and individualize intervention.
A randomized control study that analyzes the impact of a postdischarge prioritization case management strategy on readmissions for select high-risk patients that are commercially insured.
Medical utilization profiles of commercially insured members with opioid-related disorders differ depending on the code used to document the initial diagnosis in administrative claims.
The Affordable Care Act’s reductions to Medicare Advantage plan payments were not significantly associated with healthcare access or affordability for enrollees.
An analysis of the opportunity cost associated with ambulatory medical care in the United States demonstrates substantial time costs for individuals and society.
This study suggests that lower healthcare resource use and achieving low disease activity are associated with first-line abatacept compared with a first-line tumor necrosis factor-α inhibitor for patients with early rapidly progressive rheumatoid arthritis.
Automated phone and mail population outreach resulted in an almost 4-fold increase in the rate of screening for colorectal cancer even without an office visit.
This study examined employers’ understanding of rebate guarantees, dependency upon rebate dollars, and the role that pharmaceutical rebates or employer benefits consultants play in their pharmacy benefits manager selection.
A cost-utility analysis of a hub-and-spoke telestroke network showed that it was economically dominant over routine care.
A novel, simplified cost-value analysis tool was created to better differentiate the value of anticancer agents and further characterize the expected survival benefit of all patients.
Projected savings from biosimilars from 2021 to 2025 were $38.4 billion vs conditions as of quarter 4 of 2020 and were driven by new biosimilar entry. Savings were $124.5 billion under an upper-bound scenario.
Diagnosis-related group coding determines eligibility for many Medicare bundled payment initiatives. This approach excluded many patients with chronic obstructive pulmonary disease likely to benefit while including others without the disease.
This study demonstrated that a false-positive mammogram was associated with increases in outpatient visits, but not provider referrals, for 1 year post mammogram.
Prescription nonadherence in older patients with chronic health conditions resulted in more emergency department use.
Fecal immunochemical testing resulted in higher colorectal cancer screening rates than did guaiac fecal occult blood tests, with less dependence on office visits.